Financial Tearsheet

Company Overview

ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broaden access to better healthcare.

ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) system to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI -- at a fraction of the cost, and at the point-of-care.

ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally.

IR Contacts

LHA Investor Relations

Yvonne Briggs
(310) 691-7100

Stock Performance

Stock Fundamentals Value
Today's Open 0.9618
Volume 135,295
Day Range 0.9300 - 0.9800
52 Week Range 0.7030 - 3.1000
Bid/Ask 0.9600 / 0.9760
Bid/Ask Size 1,400 X 1,300
Previous Close 0.9617
Market Cap 40.18 million
Shares Outstanding 41.86 million
Dividend/Yield 0.0000 / 0.0000%
EPS (TTM) -0.359100
P/E Ratio (TTM) N/A

Recent XBRL Filings

Filing DateSort Arrow Form Type Description View
Aug 12, 2021 10-Q Quarterly report htmlhtml   xbrlxbrl  
May 17, 2021 10-Q Quarterly report htmlhtml   xbrlxbrl  
Mar 25, 2021 10-K Annual report htmlhtml   xbrlxbrl  
Nov 16, 2020 10-Q Quarterly report htmlhtml   xbrlxbrl  
Aug 14, 2020 10-Q Quarterly report htmlhtml   xbrlxbrl  

Management Team

Francois Michelon, Chief Executive Officer and Chairman

Michael Thornton, Chief Technology Officer

David Wells, Chief Financial Officer

Amy Sitzler, Vice President of Engineering and Programs

Steve Freeman, Human Resources Leader

Renaud Maloberti, Chief Commercial Officer

Board of Directors

Francois Michelon, Chairman of the Board

Louis Basenese, Director

Anthony DiGiandomenico, Director

Michael Harsh, Director

Alexander Tokman, Director